Alivus Life Sciences Ltd. benchmarking: Performance to industry peers

Financial

	Alivus Life Sciences	Neuland Laboratories	IOL Chem & Pharma
Operational Metrics
Pharmaceuticals
US DMF Filings	611.0 .	75.0 .	n/a
Unclassified
Number of ANDA's Filed	n/a	n/a	n/a
R&D as a % of Total Sales	3.6 %	4.15 %	1.01 %
Financials
5 yr Average ROE	25.27 %	16.78 %	8.9 %
5yr average Equity Multiplier	1.74	1.53	1.42
5yr Average Asset Turnover Ratio	0.71	0.73	0.99
5yr Avg Net Profit Margin	20.19 %	15.06 %	6.28 %
Price to Book	4.28	13.0	2.83
P/E	25.24	66.96	37.03
5yr Avg Cash Conversion Cycle	100.66 Days	32.22 Days	37.81 Days
Inventory Days	95.06 Days	85.47 Days	65.55 Days
Days Receivable	132.12 Days	77.32 Days	86.45 Days
Days Payable	120.47 Days	121.04 Days	100.1 Days
5yr Average Interest Coverage Ratio	371.82	23.69	15.8
5yr Avg ROCE	33.88 %	19.67 %	12.63 %
5yr Avg Operating Profit Margin	29.64 %	23.56 %	10.64 %
5 yr average Debt to Equity	0.0	0.13	0.04
5yr CAGR Net Profit	6.67 %	41.65 %	-9.63 %
5yr Average Return on Assets	14.28 %	11.14 %	6.27 %
Shareholdings
Promoter Holding	74.87 %	32.63 %	62.28 %
Share Pledged by Promoters	0.0	2.29 %	0.0
Change in Promoter Holding (3 Yrs)	-7.98 %	-3.51 %	14.09 %
Change in Mutual Fund Holding (3 Yrs)	5.13 %	10.36 %	0.0

Business

	Alivus Life Sciences	Neuland Laboratories	IOL Chem & Pharma
Product Wise Break-Up	Product Wise Break-Up Generic API 92.05 CDMO 6.57 API`s 0 Generic Drug Substances(GDS) 0 Custom Manufacturing Solutions(CMS) 0 API 0 Chemicals 0 Ethyl Acetate 0 Ibuprofen 0 Pantaprazole 0 Clopidogrel 0 Metformin 0 Others 1.38	Product Wise Break-Up Pantaprazole 0 Formulations 76.0 Chemicals 0 Clopidogrel 0 API 0 Ethyl Acetate 0 Generic API 0 API`s 0 Ibuprofen 0 Metformin 0 Custom Manufacturing Solutions(CMS) 18.0 CDMO 0 Others 6.0	Product Wise Break-Up Pantaprazole 0 Generic Drug Substances(GDS) 0 Chemicals 43.0 Clopidogrel 0 API 20.0 Ethyl Acetate 0 Generic API 0 API`s 0 Ibuprofen 37.0 Metformin 0 Custom Manufacturing Solutions(CMS) 0 CDMO 0
Location Wise Break-Up	Location Wise Break-Up India 48.28 Rest of the World 0 USA 0 Europe 0 Others 51.72	Location Wise Break-Up USA 29.35 Europe 29.86 India 30.39 Rest of the World 10.4	Location Wise Break-Up USA 0 Europe 0 India 76.0 Rest of the World 24.0
Customer Segment	Customer Segment Regulated Markets 85.0 Emerging Markets 15.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up CVS 42.0 CNS 14.0 Pain Management 4.0 Diabetes 4.0 Anticonvulsant 0 Antidepressant 0 Antibacterial 0 Others 36.0	Therapeutic Area Break-Up CVS 0 Anti-bacterial 19.72 Anticonvulsant 10.46 Antidepressant 11.8 Diabetes 0 Pain Management 0 CNS 0 Others 58.02	-
Acute vs Chronic	Acute vs Chronic Chronic 65.0 Acute 35.0	-	-
Customer Wise Break-Up	Customer Wise Break-Up External 65.0 GPL 35.0	-	-
Asset Break-Up - Geography Wise	Asset Break-Up - Geography Wise Others 100	-	-

Alivus Life Sciences Ltd.

Alivus Life Sciences Ltd.

Financial

Business

SIGN UP FOR FREE